These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16112193)

  • 1. Analysis of PTEN deletions and mutations in multiple myeloma.
    Chang H; Qi XY; Claudio J; Zhuang L; Patterson B; Stewart AK
    Leuk Res; 2006 Mar; 30(3):262-5. PubMed ID: 16112193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
    Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
    Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment and characterization of a cytogenetically complex Chinese multiple myeloma-derived cell line with homozygous p53 deletion and cyclin E overexpression.
    Cheng SH; Ng MH; Tsang KS; Lau KM; Chan JC; Liu HS; Chu RW; Poon CS; Ng HK
    Int J Oncol; 2004 May; 24(5):1141-8. PubMed ID: 15067335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of chromosome 12p deletion in plasma cell dyscrasias.
    Jiang N; Qi C; Yu L; Ning Y; An G; Qiu L; Chang H
    Leuk Res; 2012 Jan; 36(1):32-6. PubMed ID: 21982640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
    An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation.
    Chang H; Qi XY; Samiee S; Yi QL; Chen C; Trudel S; Mikhael J; Reece D; Stewart AK
    Bone Marrow Transplant; 2005 Nov; 36(9):793-6. PubMed ID: 16113669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent upregulation of MYC in plasma cell leukemia.
    Chiecchio L; Dagrada GP; White HE; Towsend MR; Protheroe RK; Cheung KL; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
    Genes Chromosomes Cancer; 2009 Jul; 48(7):624-36. PubMed ID: 19396865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions.
    Chang H; Sloan S; Li D; Keith Stewart A
    Br J Haematol; 2004 Nov; 127(3):280-4. PubMed ID: 15491286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.
    Chang H; Qi C; Yi QL; Reece D; Stewart AK
    Blood; 2005 Jan; 105(1):358-60. PubMed ID: 15339849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
    Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
    Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Chang H; Qi X; Jiang A; Xu W; Young T; Reece D
    Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma.
    Kaufmann H; Ackermann J; Baldia C; Nösslinger T; Wieser R; Seidl S; Sagaster V; Gisslinger H; Jäger U; Pfeilstöcker M; Zielinski C; Drach J
    Leukemia; 2004 Nov; 18(11):1879-82. PubMed ID: 15385925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53 deletion may drive the clinical evolution and treatment response in multiple myeloma.
    López-Anglada L; Gutiérrez NC; García JL; Mateos MV; Flores T; San Miguel JF
    Eur J Haematol; 2010 Apr; 84(4):359-61. PubMed ID: 20002730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A possible role of the P53 gene deletion as a prognostic factor in multiple myeloma.
    Ortega MM; Melo MB; De Souza CA; Lorand-Metze I; Costa FF; Lima CS
    Ann Hematol; 2003 Jul; 82(7):405-9. PubMed ID: 12783209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.
    Chang H; Yeung J; Qi C; Xu W
    Br J Haematol; 2007 Aug; 138(3):324-9. PubMed ID: 17555471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
    Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
    Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.
    Tessoulin B; Moreau-Aubry A; Descamps G; Gomez-Bougie P; Maïga S; Gaignard A; Chiron D; Ménoret E; Le Gouill S; Moreau P; Amiot M; Pellat-Deceunynck C
    J Hematol Oncol; 2018 Dec; 11(1):137. PubMed ID: 30545397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Various patterns of IgH deletion identified by FISH using combined IgH and IgH/CCND1 probes in multiple myeloma and chronic lymphocytic leukemia.
    Hwang Y; Lee JY; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2011 Jun; 33(3):299-304. PubMed ID: 21272268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Investigation of the molecular changes in patients with multiple myeloma by fluorescence in situ hybridization].
    Yang RF; Li CM; Chen LJ; Qiu HR; Yang H; Liu P; Xu JR; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Oct; 27(5):567-70. PubMed ID: 20931539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent involvement of heterochromatic regions in multiple myeloma-a multicolor FISH study.
    Lange K; Gadzicki D; Schlegelberger B; Göhring G
    Leuk Res; 2010 Aug; 34(8):1002-6. PubMed ID: 20022374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.